SG&A at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s SG&A?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported SG&A of $268.52M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s SG&A increased by 60.0% year-over-year, from $167.88M to $268.52M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s SG&A?
- Over 3 years (2022 to 2025), Madrigal Pharmaceuticals, Inc.'s SG&A has grown at a 156.7% compound annual growth rate (CAGR), from $48.13M to $813.83M.
- What does SG&A mean?
- The costs of selling products and managing the general administrative functions of the business.
- How do you interpret SG&A?
- Rising SG&A relative to revenue may indicate aggressive market expansion, while declining SG&A suggests improved operational leverage.
- How does SG&A compare across companies?
- Commercial-stage biopharma companies typically see SG&A rise significantly as they build out sales teams for new product launches.